Agios Pharmaceuticals, Inc. (AGIO) Ownership
AGIO ownership summary
as of October 18, 2026- Institutions
- 115.5% of shares outstanding
- Insiders
- 1.07% of shares outstanding
- Shares outstanding
- 59.7M
- Float
- 50.0M shares available to trade
- Short interest
- 11.87% 7.0M shares short
- Days to cover
- 7.21 short interest down 7.2% vs prior month
- Institutions 115.45%
- Insiders 1.07%
AGIO top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 10.81% | 6.5M | $202.2M | +701,040 (+12.2%) | June 30, 2026 |
| 2 | Farallon Capital Management, L.L.C. | 9.91% | 5.9M | $185.3M | +233,400 (+4.1%) | June 30, 2026 |
| 3 | State Street Corp | 5.92% | 3.5M | $110.7M | +168,754 (+5.0%) | June 30, 2026 |
| 4 | Lynx1 Capital Management, LP | 5.71% | 3.4M | $106.8M | +797,369 (+30.5%) | June 30, 2026 |
| 5 | D. E. Shaw & Co LP | 5.20% | 3.1M | $97.3M | +425,836 (+15.9%) | June 30, 2026 |
| 6 | Vanguard Portfolio Management, LLC | 4.85% | 2.9M | $90.8M | +287,162 (+11.0%) | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 4.49% | 2.7M | $84.0M | +49,529 (+1.9%) | June 30, 2026 |
| 8 | Armistice Capital, LLC | 4.02% | 2.4M | $75.2M | −316,000 (−11.6%) | June 30, 2026 |
| 9 | Erste Asset Management GmbH | 3.61% | 2.2M | $67.5M | −550,000 (−20.3%) | June 30, 2026 |
| 10 | Delaware Management Holdings Inc | 3.54% | 2.1M | $66.1M | +616,374 (+41.2%) | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 2.64% | 1.6M | $49.3M | +106,358 (+7.2%) | June 30, 2026 |
| 12 | Susquehanna International Group, LLP | 2.30% | 1.4M | $43.1M | +30,605 (+2.3%) | June 30, 2026 |
| 13 | ADAR1 Capital Management LLC | 2.16% | 1.3M | $40.3M | +1.1M (+815.6%) | June 30, 2026 |
| 14 | BNP Paribas Investment Partners SA | 2.14% | 1.3M | $40.1M | −300,796 (−19.0%) | June 30, 2026 |
| 15 | Dimensional Fund Advisors, Inc. | 2.09% | 1.2M | $39.1M | +97,124 (+8.4%) | June 30, 2026 |
| 16 | GW&K Investment Management, LLC | 2.02% | 1.2M | $37.8M | −8,286 (−0.7%) | June 30, 2026 |
| 17 | The Goldman Sachs Group Inc | 1.93% | 1.2M | $36.0M | +345,156 (+42.8%) | June 30, 2026 |
| 18 | UBS Group AG | 1.65% | 986K | $30.9M | +853,291 (+643.8%) | June 30, 2026 |
| 19 | Morgan Stanley - Brokerage Accounts | 1.61% | 963K | $30.2M | −4,269 (−0.4%) | June 30, 2026 |
| 20 | Nuveen, LLC | 1.46% | 874K | $27.4M | +151,212 (+20.9%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 6.0M shares and 5 cut 1.2M.
AGIO top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 3.18% | 1.9M | $59.4M | −3,480 (−0.2%) | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.87% | 1.7M | $53.7M | −32,750 (−1.9%) | September 30, 2026 |
| 3 | Nomura Small Cap Core I | 2.84% | 1.7M | $53.1M | — | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 2.56% | 1.5M | $47.9M | −17,600 (−1.1%) | September 30, 2026 |
| 5 | Vanguard Small Cap Index | 2.29% | 1.4M | $42.8M | +826 (+0.1%) | August 31, 2026 |
| 6 | Vanguard MStar Small Cap Growth Indx Inv | 1.31% | 783K | $24.5M | −6,316 (−0.8%) | August 31, 2026 |
| 7 | Fidelity Small Cap Index | 1.08% | 646K | $20.2M | +5,515 (+0.9%) | July 31, 2026 |
| 8 | BNP Paribas US Small Cap ClassicC | 1.05% | 625K | $19.6M | −1,198 (−0.2%) | August 31, 2026 |
| 9 | Strategic Advisers U.S. Total Stock | 0.90% | 540K | $16.9M | +13,439 (+2.6%) | August 31, 2026 |
| 10 | iShares Russell 2000 Value ETF | 0.87% | 522K | $16.3M | +790 (+0.2%) | September 30, 2026 |
| 11 | iShares Biotechnology ETF | 0.76% | 455K | $14.2M | −3,440 (−0.8%) | September 30, 2026 |
| 12 | BNP Paribas Health Cr Innovtr Cl Cap | 0.75% | 450K | $14.1M | −82 (−0.0%) | August 31, 2026 |
| 13 | Vanguard Russell 2000 ETF | 0.57% | 340K | $10.6M | +8,116 (+2.4%) | August 31, 2026 |
| 14 | Schwab US Small-Cap ETF™ | 0.53% | 314K | $9.8M | +207 (+0.1%) | September 30, 2026 |
| 15 | Nuveen Quant Small Cap Equity R6 | 0.52% | 308K | $9.6M | — | August 31, 2026 |
| 16 | Fidelity Extended Market Index | 0.49% | 293K | $9.2M | −2,804 (−0.9%) | August 31, 2026 |
| 17 | DFA US Small Cap I | 0.43% | 258K | $8.1M | — | August 31, 2026 |
| 18 | BlackRock Advantage Small Cap Core Instl | 0.42% | 248K | $7.8M | +32,591 (+15.1%) | August 31, 2026 |
| 19 | DFA US Micro Cap I | 0.41% | 245K | $7.7M | — | August 31, 2026 |
| 20 | AMG GW&K Small Cap Core N | 0.38% | 225K | $7.0M | +31,962 (+16.6%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
AGIO insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | James William Burns | Sell | $34.71 | 3,280 | $113,849 |
| 2026-04-02 | Sarah Gheuens | Sell | $34.71 | 2,940 | $102,047 |
| 2026-04-02 | Tsveta Milanova | Sell | $34.71 | 3,262 | $113,224 |
| 2026-04-02 | Cecilia Jones | Sell | $34.71 | 3,141 | $109,024 |
| 2026-03-05 | Krishnan Viswanadhan | Sell | $27.80 | 2,959 | $82,260 |
| 2026-03-03 | Gilbert Ray Cisneros, Jr. | Buy | $28.48 | — | — |
| 2026-01-05 | Tsveta Milanova | Sell | $27.02 | 2,872 | $77,601 |
| 2025-12-30 | Brian Goff | Sell | $27.09 | 18,703 | $506,664 |
| 2025-12-30 | Cecilia Jones | Sell | $27.09 | 2,932 | $79,428 |
| 2025-12-30 | James William Burns | Sell | $27.09 | 2,932 | $79,428 |
| 2025-12-30 | Sarah Gheuens | Sell | $27.09 | 2,932 | $79,428 |
| 2025-12-30 | Tsveta Milanova | Sell | $27.09 | 2,932 | $79,428 |
| 2025-12-11 | Gilbert Ray Cisneros, Jr. | Buy | $27.46 | — | — |
| 2025-11-12 | David Scadden | Sell | $43.84 | 200 | $8,768 |
| 2025-10-30 | Sarah Gheuens | Sell | $43.81 | 200 | $8,762 |
| 2025-10-27 | Sarah Gheuens | Sell | $43.92 | 3,302 | $145,024 |
| 2025-10-08 | David Scadden | Sell | $41.00 | 200 | $8,200 |
| 2025-09-26 | Cecilia Jones | Sell | $36.77 | 3,651 | $134,247 |
| 2025-09-05 | Theodore James Jr. Washburn | Sell | $36.87 | 8,546 | $315,091 |
| 2025-08-08 | Brian Goff | Sell | $36.67 | 11,085 | $406,487 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
AGIO shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns AGIO
Institutional investors own 115.5% of Agios Pharmaceuticals's shares and insiders 1.07%. The largest holder is BlackRock Inc with 10.81% of the shares (6.5M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 5 reduced their stake in the latest filings. Short interest is 11.87% of the float, or 7.21 days of average trading volume. The share count rose 66.1% since 2014.
Related: AGIO analyst forecast, AGIO key metrics. See the AGIO stock overview for the latest quote and news.
AGIO ownership FAQ
Who owns the most Agios Pharmaceuticals stock?
The largest shareholders of Agios Pharmaceuticals are BlackRock Inc (10.81%), Farallon Capital Management, L.L.C. (9.91%), State Street Corp (5.92%), Lynx1 Capital Management, LP (5.71%), D. E. Shaw & Co LP (5.20%).
What percentage of Agios Pharmaceuticals is owned by institutions?
Institutions hold 115.5% of Agios Pharmaceuticals's shares outstanding; insiders hold 1.07%.
Which funds own Agios Pharmaceuticals?
The largest fund holders of Agios Pharmaceuticals are Vanguard MStar Total Stk Mkt Idx Invest (3.18%), State Street® SPDR® S&P® Biotech ETF (2.87%), Nomura Small Cap Core I (2.84%), iShares Russell 2000 ETF (2.56%), Vanguard Small Cap Index (2.29%).
What is Agios Pharmaceuticals's short interest?
7.0M shares of Agios Pharmaceuticals were sold short, 11.87% of the float; at the average daily volume it would take 7.21 days to cover.
Are insiders buying or selling Agios Pharmaceuticals?
Of the latest 20 reported insider transactions in Agios Pharmaceuticals (since August 8, 2025), 2 were purchases and 18 were sales.
How many shares of Agios Pharmaceuticals are outstanding?
Agios Pharmaceuticals has 59.7M shares outstanding, of which 50.0M are in the public float.